







































Chronological age does not always accurately reflect 
functional status and life expectancy. Frail patients 
exhibit severely reduced physiological reserves that 
render them susceptible to minor stressors. More and 
more oncological therapies become available to older 
cancer patients, but an accurate evaluation of clinical 
frailty and general health status is crucial in treatment 
decision making. Geriatric assessment (GA) is currently 
the gold standard to evaluate the global health status and 
clinical frailty level of individuals [1] and is feasible in 
clinical practice [2], but has several drawbacks. Firstly, it 
is time-consuming and therefore difficult to integrate in 
routine clinical  practice,  although  the  use  of  screening 
 
 






































tools might partly overcome this problem [3]. Secondly, 
although GA corresponds with important outcome 
measures like patient survival and toxicity of treatment, 
its predictive capacity is moderate, and there is certainly 
room for better tools. Thirdly, as it does not yield a 
validated ‘end score’, it is difficult to precisely quantify 
the patients’ global health status. For this reason, some 
attempts to summarize and categorize GA results have 
been proposed in geriatric oncology such as the Balducci 
score, but the included elements and cut-offs are 
arbitrary, and do not capture the complexity of the entire 
ageing process (e.g. age ≥ 85 is sufficient to be 
categorized as ‘frail’, although it has been stated in the 
geriatric literature that more than half of patients above 
85 are actually not frail) [4].  





















Abstract: Older  cancer  patients  are  a  highly  heterogeneous  population  in  terms  of  global  health  and  physiological
reserves, and it is often difficult to determine the best treatment. Moreover, clinical tools currently used to assess global
health require dedicated time and lack a standardized end score. Circulating markers of biological age and/or fitness could
complement or partially  substitute  the existing  screening  tools.  In  this  study we explored  the  relationship of potential
ageing/frailty biomarkers with age and clinical frailty. On a population of 82 young and 162 older non‐metastatic breast
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Several biological ageing and frailty markers described 
in experimental geriatrics have been proposed to reflect 
‘biological age’ more accurately than clinical 
assessment [5], but this still needs to be proven. In fact, 
it is not always clear whether these biomarkers merely 
reflect chronological age, or rather the presence of 
clinical frailty. Anyhow, these ageing/frailty biomarkers 
have not yet filled the gap from bench to bedside to 
date. In addition, it should be noted that the 
oncogeriatric field represents a specific niche where 
extrapolation of general findings from geriatrics 
research may not be fully valid.  
 
Telomere length represents one of the best documented 
markers of ageing. As telomeres were shown to represent 
some type of cellular ‘mitotic clock’, mean leukocyte 
telomere length is commonly accepted as a promising 
ageing biomarker. Indeed, progressive telomere attrition 
with increasing age has been reported repeatedly. 
Moreover, shorter telomeres have been linked to age-
related disorders such as dementia, cardiovascular 
diseases, osteoporosis, chronic obstructive lung diseases, 
cancer, and, most importantly, to a significantly higher 
mortality rate in the elderly [6]. The association between 
telomere length and frailty or disability is however much 
less clear from the literature.   
 
Plasma IL-6 levels have also been associated with 
mortality and/or worse outcome of several diseases, 
particularly cardiovascular pathology [7-9]. Several 
investigators have specifically linked circulating IL-6 
levels to the frailty syndrome [10-13]. Notably, IL-6 
rising is not an isolated phenomenon but must be seen 
in the context of a general age-related increase in 
inflammation markers, called “inflammageing” [14]. 
Similar age-related differences have also been described 
for certain inflammatory chemokines such as MCP-1 
(also named CCL2, CC-chemokine ligand 2) [15-19] , a 
protein known for its potent ability to attract and 
activate monocytes/macrophages. Circulating levels of 
RANTES, another member of the CC-chemokine 
subfamily, tend to change during ageing [19]. In 
addition to the above described molecules, certain 
endocrine markers also show age-related changes. More 
specifically,  IGF-1 is inversely correlated with 
increasing age [20]. In mice models, disruption of the 
GH/IGF-1 signaling network resulting in IGF-1 
reduction is associated with increase in oxidative stress 
in the liver, reduced lifespan, and reduced skeletal 
density [21]. In humans, low IGF-1 levels have been 
associated with frailty and decreased functionality [22]  
Although these candidate ageing/frailty biomarkers 
have been described in the geriatric field, their value in 
the clinical practice is far from established, and they 
have not formally been correlated with the frailty 
syndrome [23]  in older cancer patients. The present 
study was undertaken to validate the five potential 
ageing/frailty markers mentioned above in a 
retrospective cohort of older breast cancer patients. In 
particular, we wanted to investigate the relationship 
between these markers and calendar age on the one 
hand, and with the different components of standard 




Patient and tumor characteristics of included subjects 
 
In total, 244 patients were included in the analysis, of 
which 82 and 162 were assigned to the young and older 
patient groups, respectively. Median ages in the young 
and older groups were 40.0 years (range 27-56) and 
76.0 years (range 70-90), respectively. Clinical tumor 
characteristics are displayed in Table 1.  Descriptive 
statistics of all geriatric test items performed on patients 
from the older cohort (screening tools and geriatric 
assessment) are summarized in Table 2. Dependency at 
ADL was noted for 49.4% of patients, and 53.9% of 
patients showed dependency at iADL. According to 
Balducci’s criteria, 24.1% of older patients (N=162) 
scored ‘fit’, 25.3% ‘vulnerable’ and 50.6% ‘frail’. Our 
newly developed LOFS could be calculated only for 
patients who completed all the tests contributing to the 
scoring (N=130), and the median score was 8 (Q1= 7, 
Q3= 9). 
 
Correlation of ageing biomarkers with calendar age 
 
Four of the measured biomarkers showed significant 
association with calendar age (Figure 1). The strongest 
association was found for circulating IGF-1 levels (Fig. 
1A). The plasma biomarkers IL-6 and MCP-1 also 
showed significant age-related changes, whereas no 
significant relationship with age could be demonstrated 
for RANTES. Mean leukocyte telomere length, 
measured as T/S ratio (which could be measured in 76 
young and 120 old patients), significantly decreased 
with increasing age.  
 
Relation between ageing biomarkers and clinical 
markers of frailty  
 
First, we correlated the different biomarkers with frailty 
level according to the Balducci score. We found no 
difference in mean leukocyte telomere length between 
‘fit’, ‘vulnerable’ and ‘frail’ patients (N=120), median 
T/S ratios being 0.6, 0.7 and 0.7, respectively (p = 
0.391). Likewise, IGF-1, RANTES and MCP-1 plasma 
levels did not show any correlation with Balducci 
category (all p>0.4).  In contrast, IL-6 plasma levels 
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were significantly different between the 3 Balducci 





















































and frail subjects were 1.4, 2.3 and 2.8 pg/ml, 
























































Clinical characteristics Young patients Older patients 
 N=82 N=162 
Age (median in years, [IQR]) 40.0 [37.0 - 44.0] 76.0 [72.0 - 80.0] 
BMI (median, [IQR]) 23.0 [21.3 - 25.6] 26.5 [23.9 – 29.8] 
Neoadjuvant hormonal treatment (N/total, %) 8/82 (9.8%) 18/162 (11.1%) 
Grade (%)   
I 14.6 15.4 
II 47.6 47.5 
III 37.8 36.4 
unknown 0 0.6 
pTa (N/total, %)   
1 35/74 (47.3%) 55/144 (28.1%) 
2 33/74 (44.6%) 79/144 (54.9%) 
3 4/74 (5.4%) 8/144 (5.6%) 
4 1/74 (1.4%) 2/144 (1.4%) 
x 1/74 (1.4%) 0/144 (0%) 
pNa (N/total, %)   
0 44/74 (59.5%) 83/144 (57.6%) 
1 15/74 (20.3%) 42/144 (29.2%) 
2 9/74 (12.2%) 10/144 (6.9%) 
3 6/74 (8.1%) 8/144 (5.6%) 
x 0/74 (0%) 1/144 (0.7%) 
Histological subtype (N/total, %)   
ductal 74/82 (90.2%) 111/162 (68.5%) 
lobular 8/82 (9.8%) 25/162 (15.4%) 
ductal + lobular 0/82 (0%) 2/162 (1.2%) 
ductal + other 0/82 (0%) 5/162 (3.1%) 
other 0/82 (0%) 19/162 (11.7%) 
‘Molecular’ subtype (N/total, %)   
Lum A 49/82 (59.8%) 99/162 (61.1%) 
Lum B 15/82 (18.3%) 29/162 (17.9%) 
Lum B - Her2 6/82 (7.3%) 12/162 (7.4%) 
Her2 4/82 (4.9%) 8/162 (4.9%) 
























































































































 N %  95% CI 
    
ECOG-PS (0–5) 153   
Score 0 = asymptomatic 85 55.6 47.5 – 63.6 
Score 1 = symptomatic but completely ambulatory  45 29.4 22.0 – 36.8 
Score 2 = symptomatic, <50% in bed during the day  4 2.6 0.02 –   5.2 
Score 3 = symptomatic, >50% in bed, but not bedbound  17 11.1 6.0 – 16.2 
Score 4 = bedbound 2 1.3 0 –   3.1 
    
fTRST 161   
Absence of a geriatric risk profile: score 0  41 25.5 18.6 – 32.3 
Presence of a geriatric risk profile: score ≥ 1 120 74.5 67.7 – 81.4 
    
G8 (0–17) 141   
Absence of a geriatric profile: score >14 62 44 35.7 – 52.3 
Presence of a geriatric profile: score ≤14 79 56 47.7 – 64.4 
    
ADL (6–24) 162   
Independent: score 6 82 50.6 42.8 –58. 5 
Dependent: score ≥ 7 80 49.4 41.5 – 57.2 
    
    
iADL (0–8) 142   
Completely independent: score 8  67 47.18 38.8 – 55.6 
Dependent: score <8 75 52.82 44.4 – 61.2 
    
MMSE (0–30) 156   
Score ≥24 = normal cognition 142 91 86.4 – 95.6 
Score 18–23 = mild cognitive decline 13 0.3 0 – 1.2 
Score ≤17 = severe cognitive decline 1 0.6 0 – 1.9 
    
GDS-15 156   
      Score 0-4 = not at risk for depression 134 85.9 80.3 – 91.4 
      Score 5-15 = at risk for depression 22 14.1 8.5 – 19.7 
    
MNA-SF (0–14) 141   
Normal nutritional status: score ≥12 79 56 47.7 – 64.4 
Risk of malnutrition: score ≤11 62 44 35.6 – 52.3 
    
MNA (0–30) 68   
Score ≥24 = normal nutritional status 21 30.9 19.7 – 42.1 
Score 17 to 23.5 = risk of malnutrition 45 66.2 54.7 – 77.6 
Score <17 = malnutrition 2 2.9 0 –   7.0 
    
CCI (0–37) 162   
No comorbidities (score 0) 93 57.4 49.6 – 65.2 
Comorbidity score 1 34 21 14.6 – 27.4 
Comorbidity score ≥2 35 21.6 15.1 – 28.1 
    
 
  

















































































































LOFS 130   
0 0 0   – 
1 6 4.6 00.9 – 08.3 
2 2 1.5 0 – 03.7 
3 2 1.5 0 – 03.7 
4 1 0.8 0 – 02.3 
5 8 6.2 1.9 – 10.4 
6 11 8.5 3.6 – 13.3 
7 24 18.5 11.7 – 25.3 
8 24 18.5 11.7 – 25.3 
9 26 20 13.0 – 27.0 
10 26 20 13.0 – 27.0 
    
Balducci score 162   
Fit 39 24.1 17.4 – 30.8 
Vulnerable 41 25.3 18.5 – 32.1 
Frail 82 50.6 42.8 – 58.5 
 
Abbreviations: N= number of patients; 95%CI = 95% confidence interval. LOFS: Leuven Oncogeriatric Frailty 
Score; ECOG-PS: Eastern Cooperative Oncology Group Performance status; fTRST: Flemish version of the 
Triage Risk Screening Tool; ADL: Activities of Daily Living; iADL: instrumental Activities of Daily Living; 
MMSE: Mini Mental State Evaluation; GDS: Geriatric Depression Scale; MNA: Mini Nutritional Assessment; 
MNA-SF: MNA-Short Form; CCI: Charlson Comorbidity Index 
 
Figure 1. Trends of  the 4 biomarkers showing significant association with chronological age.  (A) Mean  telomere
length (expressed as T/S ratio) versus age. N=196, Spearman correlation coefficient (rs) = ‐0.396, p<0.0001. (B) IL‐6 versus age.
















































Next, we studied the relationship between the different 
biomarkers and LOFS, and made similar observations. 
No association was found between LOFS and telomere 
length, IGF-1, RANTES or MCP-1. For IL-6 however, 
a significant correlation with LOFS was observed 
(p=0.0131) (Table 3). 
 
Lastly, we evaluated possible correlations of the 
different biomarkers with all the separate GA items 
that are evaluated on a semi-continuous scoring scale: 
ECOG-PS, fTRST, G8, ADL, iADL, MMSE, GDS15, 












































RANTES and MCP-1 correlated with any of the above 
mentioned items (all p>0.070, data not shown). 
Circulating levels of IGF-1 were inversely correlated 
with CCI (N=133; Spearman correlation coefficient= -
0.195, p= 0.0248) (Supplementary Table 2) but not with 
any of the other GA parameters. The most convincing 
results were obtained for IL-6 (Table 3): there was a 
significant correlation with ECOG-PS, ADL, iADL, and 
a borderline significant correlation with the CCI 
(p=0.0539). IL-6 levels were, however, not associated 
with MMSE, MNA-SF, nor with any of the geriatric 




GA scores IL-6 
 N rs p 
LOFS 129 -0.218 0.0131 
ECOG 149 0.244 0.0028 
fTRST 157 0.078 0.3288 
G8 137 -0.129 0.1320 
ADL24 145 0.205 0.0134 
IADL8 141 -0.202 0.0163 
MMSE 152 -0.093 0.2525 
GDS_15 152 0.028 0.7329 
MNA-SF 137 -0.118 0.1691 
MNA30 65 -0.368 0.0026 
CCI 158 0.154 0.0539 
 
Abbreviations: N = number of patients, rs = Spearman correlation coefficient, p= p value. LOFS: Leuven 
Oncogeriatric Frailty Score; ECOG-PS: Eastern Cooperative Oncology Group Performance status; fTRST: 
Flemish version of the Triage Risk Screening Tool; G8: /; ADL: Activities of Daily Living; iADL: instrumental 
Activities of Daily Living; MMSE: Mini Mental State Evaluation; GDS: Geriatric Depression Scale; MNA-SF: 
Mini Nutritional Assessment-Short Form; CCI: Charlson Comorbidity Index 
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examined if IL-6 levels were associated with the 
incidence of falls during the past year. Although 
patients giving a positive answer to this question 



















































value 2.7 pg/ml versus 2.3 pg/ml for patients giving a 
negative response), the difference was not statistically 
significant (p=0.154). Similarly, none of the other 




















































Figure  2.  Boxplot  showing  the  relation  between  plasma  IL‐6  and  frailty  status  determined  by  Balducci  Frailty
Score.  Frailty groups according to Balducci’s test are displayed on the X axis. In each group, some extreme values
are not shown for graphical reasons (2 values in ‘fit’, 2 values in ‘vulnerable’, and 8 values in ‘frail’ group). 
Table 4. Correlations between biomarkers in the entire cohort (young and older patients). 
 




Telomere length IL-6 -0.15553 0.0317 
 MCP-1 -0.13009 0.0721 
 RANTES -0.04132 0.5693 
 IGF-1 0.25608 0.0006 
IL-6 MCP-1 0.22944 0.0004 
 RANTES 0.02476 0.7051 
 IGF-1 -0.24374 0.0003 
MCP-1 RANTES 0.01760 0.7871 
 IGF-1 -0.34022 <.0001 
RANTES IGF-1 0.07644 0.2667 
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Correlations between the different ageing biomarkers 
  
We also evaluated possible relationships between the 
different ageing biomarkers. Table 4 shows that, except 
for RANTES, all the biomarkers (telomere length, IL-6, 
MCP-1, IGF-1) correlated with each other to a lesser or 
higher extent. 
 
Correlations between ageing biomarkers and tumor 
characteristics  
 
No significant association was found between any of the 
ageing biomarkers and tumor size (pT)[29], nodal status 
(pN), histologic breast carcinoma subtype (ductal, 
lobular, combined or other) or molecular tumor subtype 
(luminal A, luminal B/Her2-, luminal B/Her2+, non-




In this study we have investigated the associations 
between calendar age and clinical ageing/frailty on the 
one hand, and a panel of biological markers, measurable 
in blood, on the other hand. In addition, we also 
describe a novel approach to compile the results of the 
different geriatric assessment test items into a single 
output score on a 10-points scale. 
 
Geriatric assessment is currently the best way to assess 
the level of fitness in oncogeriatric patients, in order to 
plan an adequate therapeutic strategy. It allows to detect 
unknown geriatric problems and to adapt treatment 
regimens accordingly [2, 30-32]. GA consists of 
different questionnaires and tests that have been 
validated independently, each reflecting a specific 
aspect of the geriatric phenotype. However, interpreting 
GA results and translating them into a risk profile is 
challenging, since no real ‘end score’ exists. Several 
frailty models have been developed in general 
geriatrics, but Balducci and Extermann were the first to 
suggest a classification of cancer patients into 3 groups 
(‘fit’, ‘vulnerable’ and ‘frail’) depending on their GA 
result [33], with the purpose of guiding treatment 
decisions and predict life expectancy. For instance, frail 
patients would solely be administered palliative 
treatments, while a specific individualized approach 
(e.g. dose reduction at the start with subsequent 
escalation) would be applied for vulnerable patients. 
Considering the complexity of ageing, and the wide 
variety of aspects that are evaluated by GA, the 
Balducci classification is a simplified tool with many 
shortcomings and was probably meant as a starting 
point for future refinement.  We have developed a new 
method, designated LOFS, to calculate a global GA end 
score that integrates 5 fundamental aspects determining 
a patient’s fitness/frailty status, i.e. capability to 
autonomously perform activities of daily living (ADL 
and iADL), mental state (MMSE), nutritional state 
(MNA-SF) and comorbidities (CCI). A direct 
comparison between Balducci score and LOFS was not 
possible, as there is no gold standard to compare them 
to. However, LOFS is more refined than the Balducci 
score, as its semi-continuous scoring system is in line 
with recent evolution in the geriatric research field, 
where frailty is more and more seen as a continuous 
event (cumulative deficit model) [4]. In keeping with 
the Balducci criteria, a patient can be categorized as 
‘frail’ solely based on advanced age (85 years or older), 
or sporadic incontinence. However, patients fulfilling 
these criteria are not necessarily frail individuals with a 
global health status being too poor to tolerate cancer 
chemotherapy. Undertreatment, due to fear of toxicity 
or intolerance, is a frequent problem in older breast 
cancer patients and results in an increased risk of 
relapse [34]. The value of LOFS in predicting toxicity 
of treatment and general outcome (survival) of patients 
will be comprehensively assessed in future studies (we 
are currently conducting a large survival study in a 
separate cohort).  
 
As GA alone is not sufficient to predict outcome and 
tolerance to chemotherapy[35, 36], there is an 
increasing interest to integrate it with specific 
biomarkers that reflect biological ageing and frailty in 
individuals affected by cancer, in order to get a more 
complete picture of the patients’ physiological reserves 
and capability to tolerate chemotherapy.  Despite the 
well-documented correlation of several measurable 
molecules with age/frailty in the general (non-cancer) 
population [9-13, 15, 17, 18, 20, 22], none of these 
markers has emerged as “the” ageing biomarker of 
choice. Even less information is available on ageing 
biomarkers that could be valuable in oncogeriatric 
patients. This is partly due to complexity arising from 
the extent of the malignant disease, mechanisms of 
ageing and possible interactions between these two 
processes. We have explored several candidate ageing 
biomarkers in our breast cancer study cohort, and 
examined their relation to the patient’s frailty status, 
either according to Balducci or our newly developed 
LOFS. Our results show that the biomarkers correlate at 
least as good with age/frailty defined according to 
LOFS, as Balducci. In our patient population, plasma 
IL-6 emerged as the strongest frailty marker. It was not 
only associated with Balducci category and LOFS, but 
also with other items of the GA not included in the 
calculation of these global scores, like for instance 
ECOG-PS. A correlation between plasma IL-6, 
ageing/frailty and even with mortality had previously 
been consistently observed in numerous studies on 
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general (non-cancer) geriatric populations [7-13, 37]. We 
have shown that plasma IL-6 also correlates with 
calendar age. Age-related rising of circulating IL-6 is 
believed to originate from ageing of the immune system, 
generally referred to as ‘immunosenescence’. This results 
in an altered profile of circulating leukocytes, but also 
provokes an imbalance of pro- and anti-inflammatory 
cytokines and chemokines. This ageing-related pro-
inflammatory status, called ‘inflammageing’, has been 
correlated with dementia, Parkinson’s disease, 
atherosclerosis, type 2 diabetes, sarcopenia, functional 
disability and death [14, 38]. We now demonstrated that 
circulating IL-6 levels are associated with both 
chronological age and frailty in a selected breast cancer 
population. The additional predictive value of IL-6, 
supplementary to that of clinical frailty assessment, for 
outcome and treatment toxicity in (breast) cancer patients 
should be explored in the future.  
 
For plasma MCP-1 we found a strong correlation with 
calendar age but no association with clinical frailty. 
Although association of MCP-1 with atherosclerosis has 
been documented, circulating MCP-1 levels seem to be 
primarily correlated with chronological age [15-19]. In 
line with these earlier reports, our results suggest that 
MCP-1 merely reflects chronological age, which does 
not always accurately mirror the patient’s physiological 
reserves and functional status. The lack of association 
with clinical frailty does not make MCP-1 an attractive 
biomarker to be used in the clinic for treatment 
decisions. Data on the chemokine RANTES/CCL5 are 
even less consistent: RANTES has been proposed as an 
ageing biomarker because its plasma concentrations 
have been shown to increase with ageing [39], but in 
our study we did not find any association with calendar 
age nor with clinical frailty. 
 
As expected, mean leukocyte telomere length inversely 
correlated with chronological age in our study 
population. However, we did not detect any correlation 
between mean telomere length in circulating white 
blood cells and functional status. Shorter telomeres have 
been linked to age related diseases, a higher mortality 
rate [6], and also to premature ageing syndromes like 
progeria or trichotiodystrophy [40, 41]. However, 
studies investigating the relationship between telomere 
length and frailty/disability showed conflicting results 
[42-48]. It has been suggested that biomarker 
associations with health outcomes may differ between 
very old and younger old populations (through a 
positive selection effect or survivor effect) [6, 45, 49].  
Our population did not contain an overload of ‘very 
old’, as the median age was 76 years and only 16% of 
patients were above 80. Nevertheless, we did not find a 
significant relationship between telomeres and frailty. It 
should be kept in mind, though, that the oncogeriatric 
population is probably a biased one, as severely frail 
older cancer patients will rarely be referred to the 
oncologists for specialist care. In this regard, 
observations made on general geriatric populations 
might not be valid in oncogeriatric populations.  
 
To our knowledge, the association between functional 
status and mean leukocyte telomere length has never 
been investigated in older cancer patients; our study is 
the first to report the lack of such correlation in this 
specific setting.  
 
The relevance of the IGF-1 pathway in mammalian 
longevity was initially demonstrated in rodents (calorie 
restriction was shown to decrease IGF-1 levels with 
increased lifespan as result) and knockout mice [50]. In 
humans, low IGF-1 levels have been shown to inversely 
correlate with increasing age [20], and some studies 
suggest a link with frailty/functionality [22, 51]. In our 
study population, IGF-1 showed no association with GA 
components, except for a significant correlation with 
CCI. Yet, compared to the other investigated molecules, 
IGF-1 showed the strongest association with calendar 
age. Thus, like plasma MCP-1, circulating IGF-1 seems 
to be linked with the chronological age but not with 
ageing-related functional decline and frailty. 
 
In conclusion, we have investigated the relationship 
between several potential biomarkers of ageing/frailty, 
and the different components of the GA, within a 
specific breast cancer population. We confirmed IL-6 as 
a promising marker in predicting frailty, besides its 
correlation with age. MCP-1, IGF-1 and leukocyte 
telomere length were correlated with chronological age, 
but not with frailty, and apparently reflect only the time 
aspect of ageing, but not the possible functional 
consequences (i.e. clinical frailty) of the ageing process. 
However, lack of correlation with frailty status at the 
time of diagnosis does not necessarily mean that these 
markers have no value in guiding treatment choices. 
Hence, the next steps to be undertaken are prospective 
validation of these and perhaps other markers like for 
instance circulating microRNAs, in predicting outcome 
including survival and short- and long term toxicity 
from different treatment modalities. We are currently 
conducting an extensive prospective ageing biomarker 
study in breast cancer patients receiving chemotherapy. 
The ultimate goal would be the identification of robust 
frailty biomarkers that can add on, or maybe even 
(partly) replace, the extensive clinical GA that is 
suggested nowadays. 
 
We also designed the LOFS, a novel comprehensive 
method to categorize patients on the basis of their GA 
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results. This new 10-point scoring system reflects the 
general condition of a patient in a more refined way and 
allows a more subtle interpretation of the GA results 
taking into account 5 crucial domains of GA, while at 
the same time retaining the simplicity of a single end 
score that is desirable for application in daily practice. 
   
The field of medicine in general, but especially geriatric 
oncology, is evolving more and more towards a patient-
tailored approach in which accurate frailty assessment 
instruments, such as easy-to-measure biomarkers and 
reliable but simple clinical evaluation tools, could be 
very helpful. 
 




1. Selection of the older patients group. From 2004 on, 
several prospective projects integrating geriatric 
assessment in older cancer patients were performed in 
our center (University Hospitals Leuven, Leuven, 
Belgium) and all results obtained throughout the years 
were gathered in a GA database. From this database, all 
patients aged ≥ 70 years with new diagnosis of early or 
locally advanced (i.e. non-metastatic), primary or 
second primary breast cancer with GA performed 
before initiation of any chemotherapy, radiotherapy or 
surgery, were retrospectively selected. Neo-adjuvant 
antihormonal treatment was allowed between the time 
of diagnosis and the time of GA, since we expected 
virtually no, or only very minor impact on the result of 
GA. From this primary selection, we chose patients for 
whom a blood sample collected at diagnosis (i.e. before 
administration of any treatment or performance of any 
surgical procedure) was available from the large-scale 
breast cancer blood bank that was established at our 
hospital from 2003 onwards by the Leuven 
Multidisciplinary Breast Center (LMBC), and that 
contains blood specimens from more than 4000 breast 
cancer patients. In total, 162 patients fulfilled all these 
inclusion criteria. 
 
2. Selection of the young patients group. A second 
group, consisting of younger breast cancer patients, was 
selected from the LMBC database and biobank. 
Inclusion was based on the same criteria as described 
above, except for age and GA. We aimed for a broad 
age range below the cut-off of 60 years. From this 
group, a final selection of 82 patients was made so as to 
ensure that both cohorts (older versus young) contained 
similar percentages of Luminal A-like, Luminal B-like, 
Luminal B-HER2 positive, HER2 positive and Triple 
Negative breast tumors, as defined in one of our 
previous publications [24].  
Collection of plasma and leukocyte DNA. Blood 
sampling and isolation of plasma (collection started in 
2003) and DNA (collection started in 2007) for 
experimental use is routinely performed in our hospital, 
in all new breast cancer patients who give written 
informed consent for the LMBC biobanking project. 
The procedures were previously described by Hatse S. 
et al. [25]. 
 
Measurements of cytokine/chemokine levels in plasma. 
IL-6 was measured using LEGEND MAXTM ELISA kit 
(BioLegend). The analysis for CCL5/RANTES, 
CCL2/MCP-1, and IGF-1 was carried out with 
Quantikine ELISA kit (R&D Systems). All procedures 
were performed following the manufacturers’ 
instructions. Read-out was performed by dual 
spectrophotometric measurement: absorbance measured 
at 570 nm was subtracted from absorbance measured at 
450 nm. All samples were assayed in duplicate. On each 
microplate, a standard curve, obtained from dilution of a 
standard with known concentration, was included. 
Concentrations of samples were calculated from the 
standard curve using a logistic curve-fitting algorithm. 
  
Mean leukocyte telomere length. Mean leukocyte 
telomere length was measured for all patients with a 
leukocyte DNA sample collected at diagnosis (i.e. 
patients diagnosed in 2007 or later). Every DNA sample 
was first tested for DNA fragmentation by 
electrophoresis on a 1% agarose gel. Fragmented DNA 
samples were excluded from further analysis. Telomere 
length was determined using the qPCR-based method 
developed by R. Cawthon [26]. Briefly, the relative 
amount of telomeric DNA (“T/S ratio”) is calculated 
based on the Cp values obtained for telomeric DNA 
(“T”) and for the single-copy housekeeping gene 36B4 
(“S”), measured in the same sample. All samples were 
assayed twice in independent qPCR runs, each time in 
triplicate wells. Each run included a dilution series (i.e. 
80, 20, 5 and 1.25 ng) of human standard DNA (Human 
Genomic DNA, Roche). The “T/S ratio” for an 
experimental sample is the amount (ng) of standard 
DNA that matches the experimental sample for copy 
number of the telomere template (“T”), divided by the 
amount (ng) of standard DNA that matches the 
experimental sample for copy number of the single-
copy gene (“S”) Primer pairs used were 5’-
ACACTAAGGTTTGGGTTTGGGTTTGGGTTTGGG
TTAGTGT-3’ and 5’-TGTTAGGTATCCCTATCCCT 
ATCCCTATCCCTATCCCTAACA-3’ for telomeres 
and 5’-CAGCAAGTGGGAAGGTGTAATCC-3’ and 
5’-CCCATTCTATCATCAACGGGTACAA-3’ for  
36B4. The reaction mixture contained 1x LightCycler 
480 SYBR Green I Master (Roche, Indianapolis, US), 
telomere or 36B4 forward and reverse primers at 0.6 
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µM (telomeres)or 0.5 µM (36B4) each, and 20 ng of 
template DNA in a total volume of 20 µL. Plates were 
run on a Roche LightCycler 480 platform, using the 
following thermal cycling program : activation for 10 
min at 95°C; two initiation cycles of 15s at 95°C 
followed by 15s at 49°C; 35 amplification cycles of 15s 
at 95°C, 10s at 60°C and 15s at 72°C. Thereafter, 
melting curves were also established to check amplicon 
purity. 
 
Geriatric assessment. Patient scores at different tests, 
included in the GA, were available from our GA 
database. The following items were mostly available: 
the screening tools G8 and Flemish version of the 
Triage Risk Screening Tool (fTRST), Eastern 
Cooperative Oncology Group Performance Status 
(ECOG-PS), functional status measured by Activities 
of Daily Living (ADL) and instrumental Activities of 
Daily Living (iADL), Geriatric Depression Scale 
(GDS-15), Mini Mental Evaluation-30, and Mini 
Nutritional Assessment- 14 items (MNA-SF). Since 
the geriatric assessments performed in the different 
oncogeriatric projects constituting our GA database 
were not exactly identical, there were rare missing 
cases for some of the scales, but for the majority, all 
scale results were available. Charlson Comorbidity 
Index (CCI) at the time of diagnosis was calculated 
retrospectively for each patient using the electronic 
patient files. More details on the scales and references 
can be found in another recently published paper from 
our group [2].  
 
Balducci score. A level of frailty was assigned to each 
patient using the criteria suggested by Balducci and 
Extermann [27, 28]. ‘fit’ was assigned to patients 
without ADL or iADL impairment (i.e. patients 
independent at all items), and with no or only mild 
comorbidities; ‘vulnerable’ was assigned to patients 
with dependency at 1 or more iADL items, and/or with 
1 or 2 severe comorbidities; ‘frail’ was assigned to 
patients ≥85 years of age, or patients dependent at 1 or 
more ADL items, and/or exhibiting 3 or more severe 
comorbidities. Patients with documentation of one or 
more geriatric syndromes (dementia, falls, delirium, 
depression, incontinence, osteoporosis, neglect and 
abuse, failure to thrive) were also categorized as 
‘frail’.  
 
Leuven Oncogeriatric Frailty Score (LOFS). In the 
geriatrics world, frailty is more and more seen as a 
cumulative deficit disorder, and should thus be 
appraised as a continuous spectrum, rather than a 
dichotomized or trichotomized status[4]. Therefore, we 
developed the LOFS, a semi-continuous frailty score, 
based on internationally validated cut-offs for ADL, 
iADL, MMSE, MNA-SF and CCI. A detailed overview 
of the score compilation is shown in Supplementary 
table 1. The scoring range for each separate test is 
trichotomized, the lowest part (worst score range for 
this particular test) resulting in a LOFS +0 (no 
contribution to the final 10-points LOFS score), the 
middle part in +1 (contribution of 1 point to the final 
score), and the highest part in +2 (contribution of 2 
points). Contributions from the 5 tests are added up to 
result in a total score on a scale from 0 (poorest score; 
patient suffering from extreme frailty) to 10 (best score, 
fit patient). Individual results from the LOFS should be 
interpreted as a gradation of severity in the spectrum of 
frailty between both extremes.  
  
Statistical analysis. We analyzed correlations between 
ageing biomarkers and calendar age, and between 
ageing biomarkers and clinical frailty (defined as by 
Balducci test or LOFS). In addition, we also studied 
correlations of ageing biomarkers with each of the 
individual geriatric assessment tools separately and 
correlations among the different ageing biomarkers. 
Since distinct breast tumor subtypes might have a 
different impact on the host and tumor stroma (e.g. 
triple negative subtype are associated with stronger 
immune response), we also studied the influence of 
tumor subtype, tumor stage (pT) and nodal status (pN) 
on the biomarkers.  
 
Associations between continuous and discrete variables 
were evaluated using the Mann-Whitney U test (for two 
levels) or the Kruskal-Wallis test (for more than two 
levels). Associations between two continuous variables, 
or between a continuous and an ordinal categorical 
variable, were analyzed by the Spearman correlation 
coefficient. Associations between two discrete variables 
were analyzed using the Fisher exact test. 
 
The cut-off for statistical significance was set at p= 0.05. 
 
Ethical aspects. The LMBC biobank project and this 
study have been approved by the Ethics Committee of 
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Geriatric test LOFS +2 LOFS +1 LOFS +0 
ADL 6 5 - 4 ≤ 3 
iADL 8 7 - 4 ≤ 3 
MMSE 30 - 28 27 - 24 ≤ 23 
MNA 14 - 12 11 - 8 ≤ 7 






Telomeres IGF-1 MCP-1 RANTES 
 N rs p N rs p N rs p N rs p 
LOFS 109 0.048 0.6174 114 0.124 0.1897 130 -0.017 0.8463 130 -0.025 0.7799 
ECOG 120 -0.068 0.4616 127 -0.094 0.2937 150 -0.026 0.7559 150 0.031 0.7108 
TRST 120 0.041 0.6604 132 -0.016 0.8537 157 0.001 0.9927 157 -0.066 0.4111 
G8 120 -0.015 0.8740 118 0.041 0.6628 139 -0.112 0.1894 139 0.010 0.9066 
ADL24 120 0.092 0.3162 123 -0.139 0.1243 146 0.002 0.9770 146 0.111 0.1815 
IADL8 108 0.056 0.5652 123 0.073 0.4211 141 0.085 0.3153 141 0.007 0.9326 
MMSE 120 0.088 0.3380 130 0.071 0.4192 153 0.153 0.0596 153 -0.058 0.4781 
GDS_15 120 0.131 0.1542 130 -0.026 0.7653 153 -0.146 0.0719 153 0.015 0.8530 
MNA14 120 -0.054 0.5559 118 0.096 0.2995 139 -0.053 0.5327 139 0.037 0.6662 
MNA30 56 0.040 0.7681 51 0.089 0.5327 66 -0.089 0.4763 66 0.029 0.8162 
CCI 120 0.009 0.9182 133 -0.195 0.0248 158 0.123 0.1244 158 -0.055 0.4905 
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Supplementary Figure 1. LOFS distribution among older patients.   
 
Supplementary Figure 2. Histogram of the age distribution of the study population. 
 (A) young patients group (median age = 40 years, IQR =   37 – 44). (B) older patients
group (median age = 76 years, IQR = 72 – 80). 
